Oxcarbazepine XR
Phase 3Small molecule
Supernus Pharmaceuticals, Inc.Oxcarbazepine XR is one of 25 small molecule programs targeting Partial Epilepsy. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Partial Epilepsy
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Vimpat
UCBApproved
Trileptal
NovartisApproved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Depakote
AbbVieApproved
Zonegran
AAzurity Pharmaceuticals
Approved
Fycompa
CCatalyst Biosciences
Approved
Benemid
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Fintepla
IImmedica Pharma AB
Approved
Neurontin
VViatris Specialty LLC
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oxcarbazepine XR. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details